Systemic TUDCA administraton decreases photoreceptor cell loss in RD. by Dimosthenis Mantopoulos (343471)

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

PF treatment decreases the levels of IL-1β(A) and TNFα(B) in plasma. by Ruo-Bing Guo (298949)

Albumin degradation in podocytes decreased with lysosome inhibition, but not proteasome inhibition. by John M. Carson (577297)

Validation of a New Scoring Scale for Behavioral Assessment of L‑Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development by Simon Loiodice (4715610)

“…The rating scale was sensitive enough to highlight a dose-dependent amantadine-mediated decrease (about 2.2-fold) in LID score. …”

Fig 5 - by Te-Hsing Hsu (16973374)

The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

“…<p>(<b>A</b>) Genome-wide expression of 5′ splice sites, 3′ splice sites, and introns are increased relative to exons upon treatment of HeLa cells with isoginkgetin (30 µM, 18 hours), based on total RNA-Seq (dUTP method <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone.0089673-Parkhomchuk1" target="_blank">[18]</a>, Illumina). …”

Recovery coefficient. by Masakazu Tsujimoto (22339504)

Subjects:

Results of dose linearity. by Masakazu Tsujimoto (22339504)

Subjects:

Probucol prevents 3-NP-induced decreases in body weight. by Dirleise Colle (422124)

Introduction of the F region decreases the amount of extracellular PSMs and increases the amount of extracellular FnbA. by Chikara Kaito (230958)

Zinc exposure decreases NR1 clusters and NMDA currents. by Jia Zhu (135506)

“…Scale bar, 50 µm. (B) and (C) show the quantification of (A). …”

Acupuncture decreases the level of p-c-Jun after SCI. by Jee Y. Lee (455790)

CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line. by Mariam El-Ashmawy (678638)

“…Immortalized HBECs with (A) lenti-<i>KRas</i>^V12, (B) lenti-<i>KRas</i>^V12 and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i>^V12, sh<i>p53</i>, and <i>myc</i> overexpression. …”

mTOR activity is decreased in KSR1-deficient T cells. by Marie Le Borgne (337225)

Lethal toxin decreases IL-22 production in human ILCs. by Sudarshan Seshadri (370894)

The utility of Hmp for NO• consumption and tolerance decreases with increased NO• delivery rate. by Jonathan L. Robinson (409406)

PR-619 decreases Smad4 expression in UUO mice. by Kotaro Soji (5638613)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”